Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population

被引:5
作者
Yonemori, Kan [1 ]
Yamaguchi, Umio [2 ]
Kaneko, Masayuki [3 ]
Uno, Hajime [3 ]
Takeuchi, Masahiro [3 ]
Ando, Masashi [1 ]
Fujiwara, Yasuhiro [1 ]
Hosono, Ako [4 ]
Makimoto, Atsushi [4 ]
Hasegawa, Tadashi [5 ]
Yokoyama, Ryouhei [6 ]
Nakatani, Fumihiko [2 ]
Kawai, Akira [2 ]
Beppu, Yasuo [2 ]
Chuman, Hirokazu [2 ]
机构
[1] Natl Canc Ctr, Breast & Med Oncol Div, Chuo Ku, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Orthoped Div, Chuo Ku, Tokyo 1040045, Japan
[3] Kitasato Univ, Grad Sch, Div Biostat, Minato Ku, Tokyo, Japan
[4] Natl Canc Ctr, Div Pediat, Tokyo 1040045, Japan
[5] Sapporo Med Coll, Sch Med, Dept Surg Pathol, Chuo Ku, Sapporo, Hokkaido 0608543, Japan
[6] Kyushu Natl Canc Ctr Hosp, Orthoped Div, Minami Ku, Fukuoka 8111395, Japan
关键词
Ewing family of tumors; predictive factor; prognostic factor; response; chemotherapy; Asian population; STEM-CELL RESCUE; MULTIMODAL THERAPY; NEUROECTODERMAL TUMOR; SARCOMA FAMILY; ADULT PATIENTS; BONE; CHILDREN; CHEMOTHERAPY; ADOLESCENTS; IFOSFAMIDE;
D O I
10.1007/s00432-007-0295-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose There is some unknown reason Ewing family of tumors (EFTs) is much less common on Asia and Africa than in the Western Caucasian population. This study analyzed the prediction of response and prognostic factors for Ewing family of tumors (EFTs) in an Asian population with a low incidence. Methods We retrospectively reviewed 94 patients with EFTs between 1978 and 2006. Fifteen patients received local therapy only. Statistical analyses were performed for 79 patients, including those who received systemic chemotherapy, to identify factors related to chemotherapy responsiveness, event-free survival, and overall survival. Results Of the 79 patients whose records were analyzed, the 5-year event-free rate and overall survival (OS) rate were 41 and 54%, respectively. The response rate to first-line chemotherapy was 61% in 70 patients with assessable lesions. A significant predictor of response was existence of a non-pelvic primary tumor (P = 0.04). Significant prognostic factors for OS were age, performance status, and metastases at the time of diagnosis (P < 0.01, respectively). Fifty-four patients had disease progression or recurrence after first-line treatment. The time to progression was 3.4 months after salvage treatment. Progression during first-line treatment was significantly associated with time to progression after salvage treatment (P = 0.01). All patients treated without chemotherapy in first-line treatment were recurred with poor prognosis. Conclusion A non-pelvic primary tumor was a favorable predictor of responsiveness to chemotherapy. Chemo-resistant patients might less benefit from second line chemotherapy. Chemotherapy in first-line treatment should not be omitted, even if primary tumor was extirpated completely.
引用
收藏
页码:389 / 395
页数:7
相关论文
共 29 条
  • [1] Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: Analysis of 359 patients at the Istituto Ortopedico Rizzoli
    Bacci, G
    Ferrari, S
    Bertoni, F
    Rimondini, S
    Longhi, A
    Bacchini, P
    Forni, C
    Manfrini, M
    Donati, D
    Picci, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) : 4 - 11
  • [2] MYELOABLATIVE RADIOCHEMOTHERAPY AND HEMATOPOIETIC STEM-CELL RESCUE IN POOR-PROGNOSIS EWINGS-SARCOMA
    BURDACH, S
    JURGENS, H
    PETERS, C
    NURNBERGER, W
    MAUZKORHOLZ, C
    KORHOLZ, D
    PAULUSSEN, M
    PAPE, H
    DILLOO, D
    KOSCIELNIAK, E
    GADNER, H
    GOBEL, U
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) : 1482 - 1488
  • [3] MULTIMODAL THERAPY FOR THE MANAGEMENT OF NONPELVIC, LOCALIZED EWINGS-SARCOMA OF BONE - INTERGROUP STUDY IESS-II
    BURGERT, EO
    NESBIT, ME
    GARNSEY, LA
    GEHAN, EA
    HERRMANN, J
    VIETTI, TJ
    CANGIR, A
    TEFFT, M
    EVANS, R
    THOMAS, P
    ASKIN, FB
    KISSANE, JM
    PRITCHARD, DJ
    NEFF, J
    MAKLEY, JT
    GILULA, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) : 1514 - 1524
  • [4] Ewing's sarcoma:: Prognosis and survival in Mexican children from a single institution
    Cárdenas-Cardós, R
    Rivera-Luna, R
    López-Facundo, NA
    Leal-Leal, C
    Gómez-Martínez, R
    Castellanos-Toledo, A
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1999, 16 (06) : 519 - 523
  • [5] Prognostic factors in Ewing's tumor of bone:: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study group
    Cotterill, SJ
    Ahrens, S
    Paulussen, M
    Jürgens, HF
    Voûte, PA
    Gadner, H
    Craft, AW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3108 - 3114
  • [6] EWS-FL11 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma
    de Alava, E
    Kawai, A
    Healey, JH
    Fligman, I
    Meyers, PA
    Huvos, AG
    Gerald, WL
    Jhanwar, SC
    Argani, P
    Antonescu, CR
    Pardo-Mindan, FJ
    Ginsberg, J
    Womer, R
    Lawlor, ER
    Wunder, J
    Andrulis, I
    Sorensen, PHB
    Barr, FG
    Ladanyi, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1248 - 1255
  • [7] VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors
    El Weshi, A
    Memon, M
    Raja, M
    Bazarbashi, S
    Rahal, M
    El Foudeh, M
    Pai, C
    Allam, A
    El Hassan, I
    Ezzat, A
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (05): : 529 - 534
  • [8] Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone
    Grier, HE
    Krailo, MD
    Tarbell, NJ
    Link, MP
    Fryer, CJH
    Pritchard, DJ
    Gebhardt, MC
    Dickman, PS
    Perlman, EJ
    Meyers, PA
    Donaldson, SS
    Moore, S
    Rausen, AR
    Vietti, TJ
    Miser, JS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (08) : 694 - 701
  • [9] Guo W, 1999, CHINESE MED J-PEKING, V112, P1101
  • [10] Localised Ewing Sarcoma/PNET of bone - Prognostic factors and international data comparison
    Jenkin, RD
    Al-Fawaz, I
    Al-Shabanah, M
    Allam, A
    Ayas, M
    Khafaga, Y
    Memon, M
    Rifai, S
    Schultz, H
    Younge, D
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 2002, 39 (06): : 586 - 593